142 related articles for article (PubMed ID: 36410546)
1. Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.
Siudut J; Pudło J; Konieczyńska M; Polak M; Jawień J; Undas A
Int J Cardiol; 2023 Feb; 373():110-117. PubMed ID: 36410546
[TBL] [Abstract][Full Text] [Related]
2. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein.
Siudut J; Ząbczyk M; Wołkow P; Polak M; Undas A; Jawień J
Vascul Pharmacol; 2022 Jun; 144():106977. PubMed ID: 35283275
[TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease.
Stępień K; Siudut J; Konieczyńska M; Nowak K; Zalewski J; Undas A
Vascul Pharmacol; 2023 Apr; 149():107153. PubMed ID: 36774992
[TBL] [Abstract][Full Text] [Related]
4. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Mrozinska S; Cieslik J; Broniatowska E; Malinowski KP; Undas A
J Thromb Haemost; 2019 Nov; 17(11):1912-1922. PubMed ID: 31323706
[TBL] [Abstract][Full Text] [Related]
5. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
6. Reduced fibrin clot permeability on admission and elevated E-selectin at 3 months as novel risk factors of residual pulmonary vascular obstruction in patients with acute pulmonary embolism.
Stępień K; Ząbczyk M; Kopytek M; Natorska J; Zalewski J; Undas A
J Thromb Thrombolysis; 2024 Feb; 57(2):248-259. PubMed ID: 37932588
[TBL] [Abstract][Full Text] [Related]
7. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Tehrani S; Mobarrez F; Antovic A; Santesson P; Lins PE; Adamson U; Henriksson P; Wallén NH; Jörneskog G
Thromb Res; 2010 Sep; 126(3):e225-31. PubMed ID: 20637495
[TBL] [Abstract][Full Text] [Related]
9. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin-mediated inhibition of prenylation of Rab27b and Rap1a in platelets attenuates their prothrombotic capacity and modulates clot structure.
Jalal MM; Whyte CS; Coxon FP; Mutch NJ
Platelets; 2023 Dec; 34(1):2206921. PubMed ID: 37139869
[TBL] [Abstract][Full Text] [Related]
11. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
Gronostaj K; Richter P; Nowak W; Undas A
Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
[TBL] [Abstract][Full Text] [Related]
12. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease.
Paszek E; Malinowski KP; Ząbczyk M; Butenas S; Undas A
Eur J Clin Invest; 2023 Sep; 53(9):e14007. PubMed ID: 37042848
[TBL] [Abstract][Full Text] [Related]
13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
14. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Undas A; Celinska-Löwenhoff M; Löwenhoff T; Szczeklik A
J Thromb Haemost; 2006 May; 4(5):1029-36. PubMed ID: 16689755
[TBL] [Abstract][Full Text] [Related]
15. Low-grade endotoxemia in acute pulmonary embolism: Links with prothrombotic plasma fibrin clot phenotype.
Ząbczyk M; Kruk A; Natorska J; Undas A
Thromb Res; 2023 Dec; 232():70-76. PubMed ID: 37949000
[TBL] [Abstract][Full Text] [Related]
16. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype.
Natorska J; Corral J; de la Morena-Barrio ME; Bravo-Pérez C; Bagoly Z; Bereczky Z; Treliński J; Witkowski M; Klajmon A; Undas A; Ząbczyk M
Thromb Haemost; 2023 Sep; 123(9):880-891. PubMed ID: 37201530
[TBL] [Abstract][Full Text] [Related]
18. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
[TBL] [Abstract][Full Text] [Related]
19. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
[TBL] [Abstract][Full Text] [Related]
20. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
